-
Tytuł:
-
No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19.
-
Autorzy:
-
Faíco-Filho KS; Department of Medicine, Discipline of Infectious Diseases, Laboratório de Virologia Clínica, Universidade Federal de São Paulo, Rua Pedro de Toledo, 781 - Vila Clementino, São Paulo, SP, 04039-032, Brazil. .
Conte DD; Department of Medicine, Discipline of Infectious Diseases, Laboratório de Virologia Clínica, Universidade Federal de São Paulo, Rua Pedro de Toledo, 781 - Vila Clementino, São Paulo, SP, 04039-032, Brazil.
de Souza Luna LK; Department of Medicine, Discipline of Infectious Diseases, Laboratório de Virologia Clínica, Universidade Federal de São Paulo, Rua Pedro de Toledo, 781 - Vila Clementino, São Paulo, SP, 04039-032, Brazil.
Carvalho JMA; Department of Medicine, Discipline of Infectious Diseases, Laboratório de Virologia Clínica, Universidade Federal de São Paulo, Rua Pedro de Toledo, 781 - Vila Clementino, São Paulo, SP, 04039-032, Brazil.
Perosa AHS; Hospital São Paulo, Universidade Federal de São Paulo, São Paulo, Brazil.
Bellei N; Department of Medicine, Discipline of Infectious Diseases, Laboratório de Virologia Clínica, Universidade Federal de São Paulo, Rua Pedro de Toledo, 781 - Vila Clementino, São Paulo, SP, 04039-032, Brazil.
-
Źródło:
-
Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] [Braz J Microbiol] 2020 Dec; Vol. 51 (4), pp. 1765-1769. Date of Electronic Publication: 2020 Oct 27.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: 2019- : Switzerland, AG : Springer International Publishing
Original Publication: Rio de Janeiro, RJ, Brasil : Sociedade Brasileira de Microbiologia
-
MeSH Terms:
-
COVID-19 Drug Treatment*
Hydroxychloroquine/*pharmacology
SARS-CoV-2/*drug effects
Viral Load/*drug effects
Adult ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Female ; Humans ; Hydroxychloroquine/therapeutic use ; Male ; Middle Aged ; Prospective Studies ; Young Adult
-
References:
-
Clin Infect Dis. 2020 Jul 28;71(15):732-739. (PMID: 32150618)
J Med Virol. 2020 Jul;92(7):814-818. (PMID: 32253759)
Travel Med Infect Dis. 2020 Mar - Apr;34:101663. (PMID: 32289548)
Lancet Infect Dis. 2020 Jun;20(6):656-657. (PMID: 32199493)
Cell Res. 2013 Feb;23(2):300-2. (PMID: 23208422)
J Korean Med Sci. 2020 Feb 17;35(6):e79. (PMID: 32056407)
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. (PMID: 32350134)
N Engl J Med. 2020 Jun 18;382(25):2411-2418. (PMID: 32379955)
Lancet Infect Dis. 2020 Jun;20(6):697-706. (PMID: 32224310)
BMJ. 2020 Jun 8;369:m2263. (PMID: 32513810)
BMJ. 2020 Apr 21;369:m1443. (PMID: 32317267)
Lancet Infect Dis. 2006 Feb;6(2):67-9. (PMID: 16439323)
Cell Res. 2020 Mar;30(3):269-271. (PMID: 32020029)
J Thromb Haemost. 2020 May;18(5):1020-1022. (PMID: 32239799)
N Engl J Med. 2020 Mar 19;382(12):1177-1179. (PMID: 32074444)
Microb Pathog. 2020 Aug;145:104228. (PMID: 32344177)
-
Contributed Indexing:
-
Keywords: COVID-19; Hydroxychloroquine; SARS-CoV-2; Viral load
-
Substance Nomenclature:
-
0 (Antiviral Agents)
4QWG6N8QKH (Hydroxychloroquine)
-
Entry Date(s):
-
Date Created: 20201028 Date Completed: 20201211 Latest Revision: 20221207
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC7592126
-
DOI:
-
10.1007/s42770-020-00395-x
-
PMID:
-
33111169
-
Background: Some studies have shown that hydroxychloroquine (HCQ) is an effective drug in reducing the in vitro replication of SARS-CoV-2. However, the in vivo effect of HCQ still unclear.
Objectives: This study aims to evaluate viral load clearance in patients with COVID-19 who underwent HCQ treatment in comparison with a control group that did not receive the drug.
Study Design: This prospective study comprised consecutive viral load measurements in patients with COVID-19 hospitalized with a moderate illness. Patients received 400 mg of HCQ every 12 h for 10 days according to the medical decision. Nasal swab samples were collected from patients during early, intermediary, and final clinical stage of COVID-19.
Results: A total of 155 samples were collected from 66 patients with COVID-19 (60% female), with a median age of 58 years. The viral load between studied groups, assumed as a semiquantitative measure of cycle threshold (Ct) values, presented no significant difference within the three consecutive measures (ΔCt) (p > 0.05). We also analyzed the ΔCt viral load at different intervals of sample collection (Δt < 7; 7-12; and > 12 days) without significant differences at any ΔCt (p > 0.05).
Conclusion: In this study, we did not observe any change in viral load reduction in vivo with the use of HCQ.
